Literature DB >> 6640836

Intra-arterial adriamycin chemotherapy for bladder cancer. Semiselective intra-arterial chemotherapy with compression of the femoral arteries at the time of injection.

T Uyama, S Moriwaki, M Yonezawa, J Fujita.   

Abstract

Twenty patients with bladder cancer were treated by semiselective intra-arterial chemotherapy with Adriamycin. Ten of them were given the agent while the femoral arteries were compressed, to prevent loss of the agent into the external iliac arteries. The other ten were given Adriamycin without this compression. Clinical and pathological responses of tumor and the side-effects were examined in these two groups. The results of the comparative study led us to the conclusion that the compression technique is a simple and valuable means of decreasing the side-effects of Adriamycin and increasing tumor response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6640836

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.

Authors:  C E Myers; W P McGuire; R H Liss; I Ifrim; K Grotzinger; R C Young
Journal:  Science       Date:  1977-07-08       Impact factor: 47.728

Review 3.  Adriamycin. A new anticancer drug with significant clinical activity.

Authors:  R H Blum; S K Carter
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

4.  Letter: Adriamycin activating a recall phenomenon after radiation therapy.

Authors:  S S Donaldson; J M Glick; J R Wilbur
Journal:  Ann Intern Med       Date:  1974-09       Impact factor: 25.391

5.  [Studies on the chemotherapy of cancer of urinary bladder. I. Clinical studies on treatment with continuous infusion of anticancer agent into the internal iliac artery].

Authors:  T Nakamura
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1969-07

6.  Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).

Authors:  G Bonadonna; S Monfardini; M De Lena; F Fossati-Bellani; G Beretta
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

7.  Advanced carcinoma of bladder: treatment using hypogastric artery infusion with 5-fluorouracil, either as a single agent or in combination with bleomycin or adriamycin and supervoltage radiation.

Authors:  J E Nevin; I Melnick; J T Baggerly; C A Easley; R Landes
Journal:  J Urol       Date:  1974-12       Impact factor: 7.450

8.  Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil.

Authors:  R J Cross; R W Glashan; C S Humphrey; R G Robinson; P H Smith; R E Williams
Journal:  Br J Urol       Date:  1976

9.  Control of local tumor growth with combined fractionated radiotherapeutic and chemotherapeutic regimens.

Authors:  L Poulakos; L L Schenken; R F Hagemann; D R Burholt; S Lesher
Journal:  J Natl Cancer Inst       Date:  1975-05       Impact factor: 13.506

10.  Clinical spectrum of anthracycline antibiotic cardiotoxicity.

Authors:  M R Bristow; M E Billingham; J W Mason; J R Daniels
Journal:  Cancer Treat Rep       Date:  1978-06
  10 in total
  2 in total

1.  Intra-arterial adriamycin chemotherapy in combination with radiotherapy for advanced bladder cancer.

Authors:  Y Sumiyoshi; T Uyama; S Kagawa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  The role of preoperative intra-arterial doxorubicin chemotherapy in combination with low-dose irradiation for bladder cancer.

Authors:  T Uyama; S Moriwaki; A Yokozeki; K Kitada; I Higa; T Shiotsu; J Fujita
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.